Dronabinol

Generic Name: Dronabinol

Brand Names: Marinol, Sativex, Syndros

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₀O_₂

CAS Number: 1972-08-3

Unique Ingredient Identifier: 7J8897W37S

Background: Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased ...

Indication: Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Associated Conditions: Anorexia, Chemotherapy-Induced Nausea and Vomiting

Associated Therapies: -

Clinical Trials

Cannabinoid Receptor (CB1) Agonist Treatment in Severe Chronic Anorexia Nervosa

Phase 3

Completed

Conditions: Anorexia Nervosa

Interventions: Drug: dronabinol
Drug: placebo

First Posted Date: 2008-09-26

Last Posted Date: 2013-05-10

Lead Sponsor: Odense University Hospital

Target Recruit Count: 24

Registration Number: NCT00760695

Locations: 🇩🇰
Odense University Hospital, Odense, Denmark

Prevention of Postoperative Nausea and Vomiting (PONV) in Surgical Patients

Not Applicable

Completed

Conditions: Postoperative Nausea and Vomiting

Interventions: Drug: Ondansetron
Drug: Dronabinol

First Posted Date: 2008-09-23

Last Posted Date: 2016-05-13

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 216

Registration Number: NCT00757822

Locations: 🇺🇸
Central Arkansas Veterans Healthcare System-John L McClellan Memorial Veterans Hospital, Little Rock, Arkansas, United States

A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy

Phase 3

Completed

Conditions: Pain
Diabetic Neuropathy

Interventions: Drug: Placebo
Drug: Sativex

First Posted Date: 2008-07-04

Last Posted Date: 2023-05-03

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 297

Registration Number: NCT00710424

Locations: 🇬🇧
Royal Hallamshire Hospital, Sheffield, Yorkshire, United Kingdom

A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia

Phase 3

Completed

Conditions: Pain
Peripheral Neuropathy

Interventions: Drug: Placebo
Drug: Sativex

First Posted Date: 2008-07-04

Last Posted Date: 2023-05-03

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 246

Registration Number: NCT00710554

Locations: 🇬🇧
Pain Clinic Office, Gartnavel General Hospital,, Glasgow, West Lothain, United Kingdom

Cannabinoids, Neural Synchrony, and Information Processing

Early Phase 1

Completed

Conditions: Psychotic Disorders
Cannabis

Interventions: Drug: Placebo
Drug: THC

First Posted Date: 2008-07-03

Last Posted Date: 2022-03-09

Lead Sponsor: Yale University

Target Recruit Count: 42

Registration Number: NCT00708994

Locations: 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States

Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis

Phase 3

Completed

Conditions: Spasticity
Multiple Sclerosis

Interventions: Drug: Placebo
Drug: Sativex

First Posted Date: 2008-06-20

Last Posted Date: 2023-05-06

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT00702468

Locations: 🇬🇧
James Paget University Hospital NHS Foundation Trust, Gorleston on Sea, Norfolk, United Kingdom

Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain

Phase 3

Completed

Conditions: Pain
Cancer

Interventions: Drug: Sativex
Drug: GW-2000-02

First Posted Date: 2008-05-12

Last Posted Date: 2023-05-03

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 43

Registration Number: NCT00675948

Locations: 🇬🇧
Shropshire and Mid-Wales Hospice, Shrewsbury, United Kingdom

Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting

Phase 3

Completed

Conditions: Chemotherapy Induced Nausea and Vomiting

Interventions: Drug: dronabinol/ondansetron
Drug: placebo
Drug: dronabinol
Drug: ondansetron

First Posted Date: 2008-03-25

Last Posted Date: 2008-04-03

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 64

Registration Number: NCT00642512

Locations: 🇺🇸
Site 943, Rancho Mirage, California, United States
🇺🇸
Site 922, Marietta, Georgia, United States
🇺🇸
Site 905, Southfield, Michigan, United States

and more 40 locations

Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting

Phase 2

Completed

Conditions: Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting
HIV Infections

Interventions: Drug: Placebo
Drug: Dronabinol

First Posted Date: 2008-03-25

Last Posted Date: 2008-04-02

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 103

Registration Number: NCT00642499

Locations: 🇺🇸
Site 914, Chicago, Illinois, United States
🇺🇸
Site 929, Sarasota, Florida, United States
🇺🇸
Site 952, Tallahassee, Florida, United States

and more 33 locations

Cannabinoid Receptor Function & Alcoholism

Phase 1

Completed

Conditions: Alcoholism

Interventions: Drug: Placebo
Drug: THC

First Posted Date: 2008-02-27

Last Posted Date: 2022-03-11

Lead Sponsor: Yale University

Target Recruit Count: 29

Registration Number: NCT00624715

Locations: 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy